key: cord-0705013-f75hggfi
authors: Schol, Jolien; Wauters, Lucas; Dickman, Ram; Drug, Vasile; Mulak, Agata; Serra, Jordi; Enck, Paul; Tack, Jan
title: United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis
date: 2021-05-03
journal: United European Gastroenterol J
DOI: 10.1002/ueg2.12060
sha: 2b40a4398bdda6997b62bf3219756541702f1c78
doc_id: 705013
cord_uid: f75hggfi

BACKGROUND: Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. METHODS: A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements. RESULTS: The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine‐2 antagonists and 5‐HT(4) receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long‐term prognosis of gastroparesis depends on the cause. CONCLUSIONS AND INFERENCES: A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis.

Gastroparesis is a condition characterized by epigastric symptoms (nausea, vomiting, postprandial fullness, early satiation, and epigastric pain) and significantly delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. 1, 2 Gastroparesis is a complication of diabetes, especially type 1 diabetes, and may also occur following upper gastrointestinal tract surgery. Nevertheless, in the largest subgroup no underlying cause is identified and these patients are referred to as having idiopathic gastroparesis. 1, 2 The epidemiology of gastroparesis is unknown, as it requires procedures such as GE tests to make a firm diagnosis. In clinical gastroenterology practice, gastroparesis is frequently encountered and considered one of the more challenging conditions, as there are uncertainties in terms of definition, symptom spectrum, diagnosis and optimal therapeutic approach, especially as there is a paucity of interventions with established efficacy. [1] [2] [3] [4] The aim of this project was to develop a European consensus on the definition, clinical characteristics, pathophysiological concepts, diagnosis and management of gastroparesis, with a focus on idiopathic gastroparesis. The results of this consensus can offer the clinician guidance in diagnosing and managing these patients, with the aim to optimizing outcomes.

(ESNM) initiated a Delphi process, to develop consensus statements on different aspects of functional dyspepsia (FD) and gastroparesis in collaboration with other European societies. The Delphi approach, which combines the principles of evidence-based medicine, supported by systematic literature reviews and a voting process, aims to determine consensus for complex problems in medicine for which evidence from controlled trials is lacking. 5 The principal steps in the process were: (1) (Table 1) .

Participants were blinded to the votes of other participants and also gave feedback on clarity of the statement and made suggestions for adapting or splitting the statements into two or more questions, or for adding additional statements on a given topic. The Core Group adjusted the statement list, generating a total of 91 statements, and subdivided the Guideline Group members into 12 Working Groups with 3-4 members each. Each Working Group was allocated statements for which they needed to conduct a systematic literature search using several relevant keywords and provide narrative substantiation of the statements. The literature review and references were made available on a share-point server, accessible to all members. This was finalized by the summer of 2019, followed by a voting round in which each statement was presented with the evidence summary, and each member indicated the degree of agreement for the statement using a 6-point Likert scale (Table 1) Consensus was defined as when at least 80% of the Consensus Group agreed (A+ or A) with a statement. The strength of evidence for each statement was scored using the GRADE system (Table 2) . 7 After the final voting round, the manuscript was drafted and circulated for final approval by the participants. The references cited in this chapter are only a selection of the articles reviewed in each area, chosen to clarify the discussion. A final meeting planned in October 2020 was canceled because of the COVID-19 pandemic.

1.1 Gastroparesis refers to a symptom or set of symptoms that is (are) associated with delayed GE in the absence of mechanical obstruction.

STATEMENT ENDORSED, overall agreement 100%: A+ 60%, A 40%, A− 0%, D− 0%, D 0%, D+ 0%. GRADE The presence of symptomatic delayed GE is mandatory for a patient to be diagnosed with gastroparesis. [1] [2] [3] [4] The delay in GE rate should be based on a well-established reference range in healthy, asymptomatic controls (usually the 97.5th percentile, reflecting a 95% normal reference range). Asymptomatic delayed GE may be present especially in diabetic patients. 8 However, it has been proposed not to include asymptomatic subjects in the diagnosis of gastroparesis. 4 Mechanical obstruction, which can also lead to a delayed GE, should be excluded. [1] [2] [3] [4] A variable range of symptoms may be present in patients with gastroparesis, including nausea, vomiting, early satiety, bloating, postprandial fullness, abdominal pain/discomfort, and anorexia. 4, [9] [10] [11] [12] A systematic review and meta-analysis, which included only studies with a high-quality emptying test showed significant associations between the presence of delayed GE and symptoms of nausea, vomiting, early satiety, postprandial fullness and epigastric pain. 9 Other studies also confirmed that gastroparesis symptoms have considerable overlap with FD defined by the Rome IV criteria. 4, 10, 11 A problem of this definition is that the association between delayed GE and symptoms may suggest that delayed GE is directly causing the symptoms. However, this conclusion should be considered with caution. 4 Symptoms occurring in subjects with delayed GE may also be associated with other types of gastric sensorimotor dysfunction, such as impaired gastric accommodation, hypersensitivity to gastric distention and uncoordinated intense motor activity in proximal small bowel. [12] [13] [14] Gastroparesis is a chronic condition and symptoms have to be present for some time before a diagnosis is triggered, and a timeframe of at least 3 months was proposed. 15 Nausea is the most common symptom in gastroparesis, affecting more than 95%, and has been associated with the severity of delay in emptying. 4, 9, 10, 16 Vomiting is associated with nausea and with more severe delay in GE. 8, 9, 17 20 A number of studies have reported the presence of pain in a large subset of gastroparesis patients, although some of these studies included patients taking opioids, which is a major confounder. 21, 22 In studies that exclude patients on opioids, pain is less prevalent, and it is also inconsistently correlated with GE delay. 4, [8] [9] [10] [11] [12] [13] 16, 17, 20 Bloating is a common symptom of functional digestive disorders including FD and IBS, but its prevalence is high in gastroparesis patients. 9 States between 1997 and 2013, with a decrease in average length of stay but an increase in the cost of each hospitalization with time. 35 Over the same time period, emergency department visits for gastroparesis more than doubled, and this was also associated with substantial healthcare costs. 36 In a population-based study in Olmsted county, overall survival of subjects diagnosed with gastroparesis was significantly lower than the age-and sex-specific expected survival computed for the reference population, and a higher mortality was seen in diabetic versus idiopathic gastroparesis. 23 In the UK CPRD database study, mortality rates were also higher in diabetic compared to idiopathic gastroparesis patients. 24 However, in these studies the excess mortality was largely driven by cardiovascular comorbidity.

No data are available on self-cost to gastroparesis patients, but they may incur both direct and indirect costs for use of OTC medications (antiemetics, antacids, and H2 receptor antagonists), alternative therapies, medical consultations, and cofinanced treatments, as well as the cost of some dietary adjustments and nutritional support, which is often not reimbursed.

In a small US gastroparesis patient cohort, the majority of patients surveyed (54%) was not employed and considered disabled. 37 Employment rates are even lower in those on opioids. 38 In a survey of almost 500 gastroparesis patients, the symptoms reduced daily activities in 67.5% and lowered annual income in 28.5%; 11% were disabled due to gastroparesis symptoms. 39 Quality of life was significantly decreased in this cohort. Also, in a large online survey of over 1400 self-reported gastroparesis patients, quality of life as measured by the 36-item short-form health survey was decreased,

mainly on the physical health component, and this was negatively correlated with increased symptom severity, especially nausea, early satiety, and abdominal pain. 40 In a study of 299 gastroparesis patients enrolled from US referral centers, anxiety and depression scores correlated with the severity of gastroparesis symptoms but did not differ between diabetic and idiopathic gastroparesis and did not correlate with the delay in GE rate. 41 In a systematic review, based on three studies in gastroparesis (n = 378) combined anxiety/depression was present in 24% of patients, severe anxiety in 12.4%, depression in 23%, and somatization in 50%. 42 Although it is often assumed that gastroparesis may lead to weight loss, this is not substantiated in the literature. In large cohorts of patients with dyspeptic symptoms, delayed GE was not associated with weight loss. 8, 43 Gastroparesis may affect adolescent and young patients. When accompanied by weight loss, an eating disorder should be excluded, especially since delayed GE is a feature of anorexia nervosa. 44, 45 Healthcare consulting in gastroparesis is likely driven by symptom severity and impact, but no data are available from the literature.

Moreover, it is not known whether healthcare consulting is driven by psychosocial comorbidity, although this seems plausible given its correlation with symptom severity. 41 A study in the United States showed regional differences in healthcare assistance in gastroparesis patients, with admissions rates independently predicted by high overall hospitalizations within a state, suggesting that access to healthcare is a factor determining healthcare consulting. In idiopathic gastroparesis, barostat studies demonstrated that 43% of patients had impaired accommodation, associated with a higher prevalence of weight loss and early satiety, 29% of patients had hypersensitivity to gastric distension, associated with higher rates of early satiety, epigastric pain, and weight loss. 12 In diabetic gastroparesis, gastric accommodation to a meal and sensory thresholds for discomfort were lower compared to healthy controls. 13 Impaired duodenal mucosal integrity, with mucosal infiltration with eosinophils and mast cells, has been reported as a putative pathophysiological mechanism in FD but studies in gastroparesis seem to be lacking. 47 Histopathological studies in an animal model of type 1 diabetes and transmural biopsy specimens from gastroparesis patients showed decreased density of interstitial cells of Cajal, possibly due to switch from anti-inflammatory M2 macrophages to pro-inflammatory M1 macrophages. 48, 49 Conflicting data exist on a possible decrease of electrically coupled platelet-derived growth factor receptor α-fibroblast-like cells in gastroparesis. 50, 51 In small patient cohort studies, fibrotic and inflammatory changes to gastric smooth muscle were reported in diabetic gastroparesis patients, but this was not confirmed in the larger NIDDK consortium cohort. 48, 49, 52 In a study which evaluated heart-rate variability responses in 41 gastroparesis patients, diabetic gastroparesis was more frequently associated with signs of vagal dysfunction than idiopathic gastroparesis. 53 In a large study of 242 patients, there were signs of both sympathetic and parasympathetic dysfunction, the latter associated with more severe symptoms and more delayed GE. 54 Few studies have evaluated the relationship between H. pylori status and GE rate, but no consistent correlation was found. [55] [56] [57] No studies evaluated gastric acid secretion, duodenal sensitivity to acid or lipids or duodenal microbiota composition in gastroparesis. There is also no consistent proof of altered release of gut peptides contributing to gastroparesis pathophysiology. 58 Several authors have reported higher degrees of anxiety and depression in gastroparesis patients. In those studies, anxiety and depression scores were related to gastroparesis symptom severity and hospitalization rates but not to disease etiology and GE rates. 16, 17, 21, 31 Both in idiopathic and in diabetic gastroparesis, hypersensitivity to gastric distension is present and, in the former group, is associated with the symptom pattern and severity (higher rates of early satiety, epigastric pain, and weight loss). 12, 13 As gastric compliance is not altered in these patients, the pathophysiology is likely to involve altered processing of incoming signals in the central nervous system. One study using evoked potentials showed altered processing of esophageal electrical stimulation signals in the brain in patients with diabetic neuropathy, and this was related to upper gastrointestinal symptom severity and quality of life impact. 59 An fMRI study showed altered connectivity of the insula and a tendency towards decreased insula gray matter volume in gastroparesis patients. 60 Only a few studies have evaluated genetic factors that predispose for the development of gastroparesis. A long repeat polymorphism in the heme oxygenase (HO1) has been associated with worse outcomes Food retention in the stomach as seen during EGD after an overnight fast has been used as a probable sign of gastroparesis in epidemiological studies, even in the presence of a normal GE test. 23 Only one retrospective analysis study specifically addressed the relationship between GE and food retention, suggesting that gastric food retention at endoscopy could be a moderately specific sign for gastroparesis, but with poor sensitivity. 62 The definition of gastroparesis implies objective delayed GE in the absence of mechanical obstruction. To date, GE scintigraphy of a SCHOL ET AL.

-293 solid-phase meal is considered the gold standard, and by consensus, the test is performed using a 99m Technetium-labeled standardized low-fat, egg meal with imaging at 0, 1, 2, and 4 h after meal ingestion. 63 The wireless motility capsule (WMC) is an FDA-approved device for the evaluation of GE. A systematic review from 2013 that included seven studies found that for the diagnosis of gastroparesis, as compared with gastric scintigraphy, WMC had a sensitivity of 59%-86% and specificity of 64%-81%. 66 The pitfall with WMC is that it is an indigestible solid and, therefore, it empties from the stomach in response to phase 3 migrating motor complexes rather than with the test meal. A further disadvantage is that WMC is relatively expensive and its availability across different centers is limited.

Gastric ultrasonography has been used to assess antral wall motion, patterns of transpyloric flow, and GE based on changes in the cross-sectional area or diameter of the gastric antrum. Gastric ultrasonography is noninvasive, safe, cheap, widely available, allows for bedside monitoring, does not expose the patient to ionizing radiation which is restricted particularly in children and pregnant women, and shows reasonably good interobserver agreement in the evaluation of liquid GE. 66 However, ultrasonography is unable to distinguish between the solid and liquid components of a meal and therefore is unsuitable to assess emptying of solids. Ultrasonography also requires an experienced technician, is user dependent, may be influenced by the presence of intragastric air or posture and is generally considered impractical for prolonged observations. 67

When small bowel obstruction is suspected, patients generally undergo abdominal radiography which is widely available, inexpensive and has a reported accuracy of 50%-86%. Where small bowel obstruction is strongly suspected, CT scanning is the most accurate examination. 68 6. Treatment A diet composed of small particle size reduces gastroparesis and reflux symptoms in patients with diabetic gastroparesis. 69 In addition, gastroparesis carries an increased risk for a diet deficient in calories, which can be corrected by nutritional support and engagement with dieticians. 17 The efficacy of PPIs in gastroparesis has not been addressed in controlled trials. However, PPI intake is high in gastroparesis patients (70% or more) and more than 50% have an overlapping GERD diagnosis. 17, 70 It has been suggested that the coexisting GERD rather than gastroparesis is the explanation for the PPI intake.

While they are recommended as first line symptomatic treatment, there are no formal studies establishing efficacy of traditional antiemetic agents in the treatment of nausea and vomiting associated with gastroparesis. 71 In the United States, metoclopramide, a dopamine-2 receptor antagonist, is approved for the treatment of gastroparesis. However, it carries a black box warning, as it is generally not well-tolerated and chronic use (>12 weeks) may lead to extrapyramidal side effects and potential irreversible tardive dyskinesia, which has been reported in a small percentage of cases. 71 In a phase 2, randomized controlled trial (RCT) on 285 diabetic patients with gastroparesis, 10 or 14 mg metoclopramide doses, administrated via nasal spray could not reduce the overall symptom scores significantly more than placebo. 72 However, when males and females were analyzed separately, a significant effect was observed in females. Reported adverse events were mainly headache, fatigue, and dysgeusia.

Domperidone is a peripherally acting dopamine-2 antagonist that decreases nausea and increases GE rates. It does not readily cross the blood-brain barrier, making it much less likely to cause extrapyramidal side effects. However, domperidone is associated with prolongation of the cardiac QTc interval which has restricted its use. 73 SCHOL ET AL.

-295

The 5-HT 3 antagonists, such as ondansetron or granisetron, also have antiemetic properties, but controlled studies in gastroparesis are lacking. An open label study suggested efficacy of granisetron transdermal patches for controlling nausea and vomiting in gastroparesis. 74 Aprepitant, a neurokinin-1 receptor antagonist approved for use for the treatment of chemotherapy-induced emesis, was efficacious in the treatment of nausea in some patients with gastroparesis and related disorders. 75 Clinical trials of prokinetic agents report that, as a group, they enhance symptoms and improve GE rate. 76 However, there is disparity, as the relationship between improvement of symptoms and enhancement of GE rate is poor but becomes significant when only high-quality emptying studies are considered. 76, 77 The availability of prokinetics is limited in many parts of the world, but new prokinetic agents are in the pipeline for the treatment of gastroparesis. 78 Nevertheless, GE rate enhancement per se cannot be used as a marker of clinical efficacy. 79 Open-label studies all reported short term (<6 months) efficacy of intrapyloric injection of botulinum toxin both on symptoms and GE in gastroparesis. 101 uncertain. 105 Only one report mentioned the occurrence of dumping syndrome in two patients after laparoscopic pyloroplasty. 106 Only a few studies in limited numbers of patients evaluated the outcomes of near-total gastrectomy with Roux-en-Y reconstruction 107,108 or completion gastrectomy. 109 with acupuncture compared to usual or medical therapy, but due to the heterogeneity and low quality of studies, and the risk of bias, the conclusion is considered uncertain. 118 Several algorithms propose nutritional support in the form of enteral or parenteral nutrition for refractory gastroparesis with weight loss and/or nutritional deficiencies. 44 In terms of the effect of gastroparesis on life expectancy, data are conflicting. Based on 86 diabetic patients who were followed for at least 9 years, delayed GE was not related with mortality after adjustment for comorbidities, 125 but 6-year follow-up data from a tertiary care setting observed that 7% had died and 22% needed long-term parenteral or enteral feeding, suggesting gastroparesis is not a benign condition. 124 Studies conducted in referral populations demonstrate no effect of delayed GE on mortality among patients with diabetes mellitus after 12-25 years of follow-up. 126, 127 In the analysis of the UK CPRD database, mortality risk was higher in diabetic compared to idiopathic gastroparesis patients (adjusted hazard ratio: 1.9, 95% CI: 1.2-3.0). 24 A population-based study compared the observed and expected mortality of patients with gastroparesis, demonstrating a significantly higher death rate in patients compared to age-and sexmatched controls, which was largely due to cardiovascular comorbidity in diabetic patients. 23

Based on the statements that achieved consensus, a number of recommendations for understanding and managing of gastroparesis can be made (Table 3) , which are summarized in Table 4 and Figure 1 . The

Delphi process also identified several areas of uncertainty, which require additional evidence or further research.

In 2, 4, 18, 19 The overlap with EPS is considered less prevalent. 4, 17, 20 There is consensus that the true epidemiology of gastroparesis is not known, but that diabetes, gastric surgery, certain neurological and connective tissue diseases, as well as the use of certain drugs are associated with an increased risk of gastroparesis. [23] [24] [25] [29] [30] [31] [32] [33] [34] The panel agreed that gastroparesis has an important impact on quality of life and healthcare costs, and also concurs that gastroparesis is often associated with psychological comorbidities such as anxiety and depression. 35, [40] [41] [42] There is no consensus that gastroparesis may lead to unintended weight loss, but when present, eating disorders must be excluded. 9, [43] [44] [45] In terms of pathophysiological mechanisms that are relevant to gastroparesis, while the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus for a direct role for delayed emptying, impaired gastric accommodation or gastric hypersensitivity in determining symptom pattern and severity. [1] [2] [3] [4] [8] [9] [10] [11] [12] [13] 16, 17, 20, 21, 32 There was also no qualifying majority support for pivotal pathophysiological roles for loss of interstitial cells of Cajal, intrinsic or extrinsic (vagus) nerves, changes in smooth muscle, peptide hormone release, gastric acid secretion, duodenal SCHOL ET AL.

Grade of evidence References [70] [71] [72] [73] [74] [75] There is borderline support (78% agreement) for the use of prokinetics as a group, but the panel agreed on the use of 5-HT 4 receptor agonists as a class. [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] There is also no consensus on the use of other neuromodulators, herbal therapies, acupuncture or psychological therapies in gastroparesis. [90] [91] [92] [93] [116] [117] [118] The same is true for invasive therapies such as botulinum toxin injection, GES, pyloric Gastroparesis is a major source of healthcare costs 3.1,

Gastroparesis is associated with a significant decrease in quality of life and with psychosocial co-morbidities 3.5,3.6

In case of weight loss, an eating disorder must be ruled out 3.8

Upper GI endoscopy to rule out mechanical obstruction and an abnormal gastric emptying test are mandatory for establishing a diagnosis of gastroparesis. Gastric emptying can reliably be assessed by scintigraphy or breath test. Additional radiological imaging can be used to exclude obstruction in case of doubt 5.1, 5.3, 5.4, 5.5, 5.8

Gastroparesis patients should be explained dietary adjustments. Dopamine-2 antagonists or 5-HT4 agonists can be used to manage symptoms 6.1, 6.7, 6.14 In case of severe weight loss in gastroparesis, nutritional support may be needed 6.39

The long-term prognosis of gastroparesis depends on the underlying cause 7.2

Abbreviation: ESNM, European Society for Neurogastroenterology and Motility.

F I G U R E 1 Schematic representation, in an algorithm-like fashion, of the outcome of the ESNM consensus on gastroparesis management. The blue arrows depict the diagnostic and therapeutic flow of the patient. Green arrows refer to risk or pathophysiological factors. The circles depict the percentage of agreement, using a green color for ≥80% consensus, light orange for consensus between 70% and 80%, and dark orange for lower levels of consensus. ESNM, European Society for Neurogastroenterology and Motility SCHOL ET AL.

-301

The most important progress with this consensus is the identification of a cardinal symptom pattern for gastroparesis: nausea or vomiting, with or without overlapping PDS. In the past, the separation of gastroparesis from FD has been an issue of controversy, and novel terms such as (diabetic) gastropathy and FD with delayed emptying have been proposed. 128, 129 The same Delphi panel for the current consensus also generated the ESNM FD guideline, confirming early satiation, postprandial fullness and epigastric pain or burning as cardinal FD symptoms. 6 

Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting

New developments in the treatment of gastroparesis and functional dyspepsia

Gastroparesis: separate entity or just a part of dyspepsia?

United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia

Delphi: myths and reality

GRADE guidelines: 3. Rating the quality of evidence

Nausea and vomiting in diabetic and idiopathic gastroparesis

Symptoms associated with delayed emptying of solids and liquids in functional dyspepsia

Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and metaanalysis

Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity

Determinants of symptom pattern in idiopathic severely delayed gastric emptying: gastric emptying rate or proximal stomach dysfunction?

Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis

Gastrointestinal motility disorders in patients with diabetes mellitus

Gastroparesis: prevalence, clinical significance and treatment

Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis

Characteristics of nausea and its effects on quality of life in diabetic and idiopathic gastroparesis

Functional gastroduodenal disorders

European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia

Rome IV Diagnostic Questionnaire complements patient assessment of gastrointestinal symptoms for patients with gastroparesis symptoms

Opioid use and potency are associated with clinical features, quality of life, and use of resources in patients with gastroparesis

Implications of the opioid epidemic for the clinical gastroenterology practice

The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted county

Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom

Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population

Viral gastroparesis: a subgroup of idiopathic gastroparesis-clinical characteristics and longterm outcomes

Gastric enterovirus infection: a possible causative etiology of gastroparesis

Post-infectious gastroparesis: clinical and electrogastrographic aspects

Clinical features of gastric emptying after distal gastrectomy

Incidence and risk factors for postsurgical gastroparesis syndrome after laparoscopic and open radical gastrectomy

Gastroparesis in non-diabetics: associated conditions and possible risk factors

Gut dysfunction in Parkinson's disease

Gastric emptying in myotonic dystrophy

Opioids in gastroparesis: bystander or cause?

Healthcare utilization and costs associated with gastroparesis

Emergency department burden of gastroparesis in the United States

The willingness of patients with gastroparesis to take risks with medications

Chronic opioids in gastroparesis: relationship with gastrointestinal symptoms, healthcare utilization and employment

Gastroparesis

The burdens, concerns, and quality of life of patients with gastroparesis

Psychological dysfunction is associated with symptom severity but not disease etiology or degree of gastric retention in patients with gastroparesis

Psychological controversies in gastroparesis: a systematic review

Functional dyspepsia, delayed gastric emptying, and impaired quality of life

The difficult patient with gastroparesis

Oesophageal and gastric motility disorders in patients categorised as having primary anorexia nervosa

Regional differences in healthcare delivery for gastroparesis

Novel concepts in the pathophysiology and treatment of functional dyspepsia

Gastroparesis: a turning point in understanding and treatment

Cellular changes in diabetic and idiopathic gastroparesis

Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa

Platelet-derived growth factor receptor α (PDGFRα)-expressing "fibroblast-like cells" in diabetic and idiopathic gastroparesis of humans

Novel surgical treatment and gastric pathology in diabetic gastroparesis

Measures of autonomic dysfunction in diabetic and idiopathic gastroparesis

Autonomic function in gastroparesis and chronic unexplained nausea and vomiting: relationship with etiology, gastric emptying, and symptom severity

Symptom patterns and pathophysiological mechanisms in dyspeptic patients with and without Helicobacter pylori

Helicobacter pylori associated gastric pathology in patients with type II diabetes mellitus and its relationship with gastric emptying: the Ankara study

Low prevalence of H. pylori infection in patients with gastroparesis

The role of GI peptides in functional dyspepsia and gastroparesis: a systematic review

The brain networks encoding visceral sensation in patients with gastrointestinal symptoms due to diabetic neuropathy

Central nervous system mechanisms of nausea in gastroparesis: an fMRI-based case-control study

Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis

Endoscopic gastric food retention in relation to scintigraphic gastric emptying delays and clinical factors

Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine

Reproducibility of gastric emptying assessed with scintigraphy in patients with upper GI symptoms

Comprehensive assessment of gastric emptying with a stable isotope breath test

Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: future research needs: identification of future research needs from comparative effectiveness review no

Reliability and interobserver variability of ultrasonographic measurement of gastric emptying rate

Novel and validated approaches for gastric emptying scintigraphy in patients with suspected gastroparesis

Review of small-bowel obstruction: the diagnosis and when to worry

A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial

Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes

Clinical guideline: management of gastroparesis

Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B randomized study

Risk of extrapyramidal side effects comparing continuous vs. bolus intravenous metoclopramide administration: a systematic review and meta-analysis of randomised controlled trials

Granisetron transdermal system for treatment of symptoms of gastroparesis: a prescription registry study

Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders

The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis

Effects of Promotility agents on gastric emptying and symptoms: a systematic review and meta-analysis. Gastroenterology

Prokinetic Effects and Symptom Relief in the Pharmacotherapy of Gastroparesis

Is making the stomach pump better the answer to gastroparesis?

Effect of itopride on gastric emptying in longstanding diabetes mellitus

Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders

Effect of tegaserod on gut transit in male and female subjects

Prucalopride in gastroparesis: a randomized placebo-controlled crossover study

Prucalopride in diabetic and connective tissue disease-related gastroparesis: randomized placebo-controlled crossover pilot trial

Prokinetics and fundic relaxants in upper functional GI disorders

Improvement of gastric emptying in diabetic gastroparesis by erythromycin

Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis

Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study

Neuromodulators for functional gastrointestinal disorders (disorders of gut−brain interaction): a Rome foundation working team report

Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial

Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study

Mirtazapine for symptom control in refractory gastroparesis

Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers

Gastric electrical stimulation for medically refractory gastroparesis

Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study

Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis

Gastric electrical stimulation improves outcomes of patients with SCHOL ET AL

gastroparesis for up to 10 years

Gastric electrical stimulation in intractable nausea and vomiting: assessment of predictive factors of favorable outcomes

Gastric electrical stimulation reduces refractory vomiting in a randomized cross-over trial

Botulinum toxin as a treatment for refractory gastroparesis: a literature review

Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis

Botulinum toxin A for the treatment of delayed gastric emptying

Gastric per-oral endoscopic myotomy: current status and future directions

Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function

Efficacy of laparoscopic pyloroplasty for the treatment of gastroparesis

Roux-Y gastrectomy for chronic gastric atony

Management of gastric emptying disorders following the Roux-en-Y procedure

The surgical treatment of chronic gastric atony following Roux-Y diversion for alkaline reflux gastritis

Completion gastrectomy for refractory gastroparesis following surgery for peptic ulcer disease. Long-term follow-up with subjective and objective parameters

Safety and long-term durability of completion gastrectomy in 81 patients with postsurgical gastroparesis syndrome

Near-total completion gastrectomy for severe postvagotomy gastric stasis: analysis of early and long-term results in 62 patients

End of the road for a dysfunctional end organ: laparoscopic gastrectomy for refractory gastroparesis

Analysis of the relationship between Helicobacter pylori infection and diabetic gastroparesis

Changes in patients' symptoms and gastric emptying after Helicobacter pylori treatment

Review article: treatment options for functional dyspepsia

Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis

Acupuncture for symptomatic gastroparesis

Management of gastroparesis-associated malnutrition

Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review

Outcome of percutaneous jejunal feeding tube placement for refractory idiopathic severe gastroparesis: a retrospective review

Outcomes and factors associated with reduced symptoms in patients with gastroparesis

A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus

Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis

Natural history of diabetic gastroparesis

Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis

Prognosis of diabetic gastroparesis-a 25-year evaluation

Diabetic gastropathy and prokinetics

Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying

How to cite this article

United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis